진폐증 시장 규모, 점유율 및 성장 분석 : 질환 유형별, 치료법별, 진단법별, 질환 중증도별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Pneumoconiosis Market size was valued at USD 1.77 Billion in 2024 and is poised to grow from USD 1.82 Billion in 2025 to USD 2.31 Billion by 2033, growing at a CAGR of 3.0% during the forecast period (2026-2033).

The global market for pneumoconiosis encompasses diagnostics, therapeutics, and occupational health services aimed at preventing and managing lung diseases linked to mineral dust inhalation. This market is critical as occupational lung diseases persist among miners, construction, and industrial workers, particularly in regions with lax safety regulations. Significant advancements from basic radiography to advanced high-resolution CT scans and biomarker tests reflect ongoing technological innovations and more stringent regulatory measures. The rise of digital imaging platforms in Southeast Asia's coal mines signals increased demand for sophisticated software globally. Furthermore, heightened implementation of occupational health programs, driven by stricter government regulations and enhanced worker safety awareness, compels companies to invest in monitoring devices and medical evaluations, thereby fostering growth for both technology providers and service consultants.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pneumoconiosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pneumoconiosis Market Segments Analysis

Global pneumoconiosis market is segmented by disease type, treatment type, diagnosis type, disease severity, end user, distribution channel and region. Based on disease type, the market is segmented into Coal Workers' Pneumoconiosis (CWP), Silicosis, Asbestosis, Mixed Dust Pneumoconiosis and Others. Based on treatment type, the market is segmented into Pharmacological Therapy, Oxygen Therapy, Pulmonary Rehabilitation, Lung Transplantation and Supportive & Symptomatic Care. Based on diagnosis type, the market is segmented into Chest X-ray, High-Resolution Computed Tomography (HRCT), Pulmonary Function Tests (PFTs), Bronchoscopy & Biopsy and Others. Based on disease severity, the market is segmented into Mild Pneumoconiosis, Moderate Pneumoconiosis and Severe/Progressive Massive Fibrosis (PMF). Based on end user, the market is segmented into Hospitals, Pulmonology Clinics, Occupational Health Centers and Ambulatory Care Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pneumoconiosis Market

The growing awareness among employers and employees regarding the risks associated with pneumoconiosis is leading to the adoption of stringent safety measures and routine health monitoring. This increased consciousness is boosting investments in protective gear and enhanced ventilation systems, and is cultivating a preventive mindset in high-risk industries. Consequently, there is a rise in demand for diagnostic services and treatment options, which facilitates market expansion through the widespread implementation of early detection initiatives and ongoing patient management approaches. This trend is particularly evident in occupational sectors such as mining, construction, and stone-cutting, which have traditionally faced higher exposure risks.

Restraints in the Global Pneumoconiosis Market

The global pneumoconiosis market faces significant constraints due to the strict evaluation processes mandated by regulatory agencies for new therapies and diagnostic tools. These rigorous approval pathways require comprehensive clinical evidence and detailed compliance documents, which can significantly prolong the time needed to introduce innovations. As a result, manufacturers may hesitate to invest in new solutions, restricting the availability of advanced treatment options and hindering market growth, despite an increasing demand for effective interventions. Additionally, discrepancies in regulatory standards among different regions further complicate the efforts of multinational companies aiming to launch synchronized products across various markets.

Market Trends of the Global Pneumoconiosis Market

The Global Pneumoconiosis market is witnessing a significant trend towards digital health integration, characterized by the adoption of advanced technologies like telemedicine platforms, AI-driven imaging analysis, and cloud-based patient registries. This shift is streamlining the diagnosis and management of pneumoconiosis, allowing for continuous remote monitoring of lung function through innovative devices. Such advancements are enhancing data sharing capabilities among healthcare institutions, thereby fostering accelerated knowledge transfer and personalized treatment options. As digital solutions gain traction, stakeholders foresee not only improved patient outcomes but also more efficient resource allocation, reflecting a transformative approach to care delivery in the pneumoconiosis landscape.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Pneumoconiosis Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Coal Workers' Pneumoconiosis (CWP)
• Silicosis
• Asbestosis
• Mixed Dust Pneumoconiosis
• Others

Global Pneumoconiosis Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Pharmacological Therapy
  • Bronchodilators
  • Corticosteroids
  • Antibiotics
  • Antifibrotic Agents
  • Others
• Oxygen Therapy
• Pulmonary Rehabilitation
• Lung Transplantation
• Supportive & Symptomatic Care

Global Pneumoconiosis Market Size by Diagnosis Type & CAGR (2026-2033)

• Market Overview
• Chest X-ray
• High-Resolution Computed Tomography (HRCT)
• Pulmonary Function Tests (PFTs)
• Bronchoscopy & Biopsy
• Others

Global Pneumoconiosis Market Size by Disease Severity & CAGR (2026-2033)

• Market Overview
• Mild Pneumoconiosis
• Moderate Pneumoconiosis
• Severe/Progressive Massive Fibrosis (PMF)

Global Pneumoconiosis Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Pulmonology Clinics
• Occupational Health Centers
• Ambulatory Care Centers

Global Pneumoconiosis Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Pneumoconiosis Market Size & CAGR (2026-2033)

• North America (Disease Type, Treatment Type, Diagnosis Type, Disease Severity, End User, Distribution Channel)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Diagnosis Type, Disease Severity, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Diagnosis Type, Disease Severity, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Diagnosis Type, Disease Severity, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Diagnosis Type, Disease Severity, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United Therapeutics Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insmed Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pliant Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avalyn Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PureTech Health plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MannKind Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United Therapeutics Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zambon S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations